Biota to Merge With Nabi and List on Nasdaq for Better Capital Access

Australian drug development company Biota, which makes the flu drug Relenza, plans to merge with U.S.-based Nabi Biopharmaceuticals to form a combined company to be listed on Nasdaq.
The Australian